TWI902867B - 基因療法 - Google Patents

基因療法

Info

Publication number
TWI902867B
TWI902867B TW110129603A TW110129603A TWI902867B TW I902867 B TWI902867 B TW I902867B TW 110129603 A TW110129603 A TW 110129603A TW 110129603 A TW110129603 A TW 110129603A TW I902867 B TWI902867 B TW I902867B
Authority
TW
Taiwan
Prior art keywords
seq
nucleotide sequence
pgrn
sequence
mecp2
Prior art date
Application number
TW110129603A
Other languages
English (en)
Chinese (zh)
Other versions
TW202221018A (zh
Inventor
妮姬塔 達拉
阿咪 卡巴迪
托沙 羅西特 巴特
派翠克 馬克 多尼
阿穆拉 尼席 史里瓦斯塔瓦
Original Assignee
比利時商Ucb生物製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=77655525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI902867(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 比利時商Ucb生物製藥公司 filed Critical 比利時商Ucb生物製藥公司
Publication of TW202221018A publication Critical patent/TW202221018A/zh
Application granted granted Critical
Publication of TWI902867B publication Critical patent/TWI902867B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110129603A 2020-08-12 2021-08-11 基因療法 TWI902867B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063064431P 2020-08-12 2020-08-12
US63/064,431 2020-08-12

Publications (2)

Publication Number Publication Date
TW202221018A TW202221018A (zh) 2022-06-01
TWI902867B true TWI902867B (zh) 2025-11-01

Family

ID=77655525

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110129603A TWI902867B (zh) 2020-08-12 2021-08-11 基因療法

Country Status (19)

Country Link
US (1) US20230295657A1 (cg-RX-API-DMAC7.html)
EP (1) EP4196171A1 (cg-RX-API-DMAC7.html)
JP (1) JP7860958B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230044506A (cg-RX-API-DMAC7.html)
CN (1) CN116113441B (cg-RX-API-DMAC7.html)
AR (1) AR123206A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021325717A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002374A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188748A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000419A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000444A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP23016688A (cg-RX-API-DMAC7.html)
IL (1) IL300294A (cg-RX-API-DMAC7.html)
MX (1) MX2023001701A (cg-RX-API-DMAC7.html)
PE (1) PE20230914A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550145A1 (cg-RX-API-DMAC7.html)
TW (1) TWI902867B (cg-RX-API-DMAC7.html)
WO (1) WO2022034130A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202300378B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022131322A1 (cg-RX-API-DMAC7.html) * 2020-12-17 2022-06-23
IL312340A (en) * 2021-10-28 2024-06-01 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
GB202216168D0 (en) 2022-10-31 2022-12-14 UCB Biopharma SRL Route of administration
WO2024163823A1 (en) * 2023-02-02 2024-08-08 Shape Therapeutics Inc. Tissue-specific enhancers for regulating transcription
JP2026509301A (ja) * 2023-03-14 2026-03-17 ユーシービー バイオファルマ エスアールエル 遺伝子治療
CN121335978A (zh) * 2023-06-16 2026-01-13 舒泰神(北京)生物制药股份有限公司 一种人源MeCp2启动子及其用途
WO2025213097A1 (en) * 2024-04-05 2025-10-09 The Children's Hospital Of Philadelphia Novel gene therapy constructs for stxbp1 haploinsufficiency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151884A1 (en) * 2016-03-02 2017-09-08 The Children's Hospital Of Philadelphia Therapy for frontotemporal dementia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045536A1 (en) * 2007-12-21 2011-02-24 Novartis Ag Mammalian expression vector
CN104583402A (zh) * 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节mecp2表达的组合物和方法
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
CN114717264A (zh) * 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
AU2015349759B2 (en) * 2014-11-21 2022-01-06 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
JP6754361B2 (ja) * 2014-12-16 2020-09-09 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 若年型バッテン病のための遺伝子療法
TWI601821B (zh) * 2016-04-15 2017-10-11 中央研究院 治療神經發展性疾病
WO2020081490A1 (en) * 2018-10-15 2020-04-23 Voyager Therapeutics, Inc. EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151884A1 (en) * 2016-03-02 2017-09-08 The Children's Hospital Of Philadelphia Therapy for frontotemporal dementia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
期刊 Gray, Steven J et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Human gene therapy vol. 22 2011 1143-53
期刊 Gray, Steven J et al. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Human gene therapy vol. 22 2011 1143-53;期刊 Holehonnur, Roopashri et al. The production of viral vectors designed to express large and difficult to express transgenes within neurons. Molecular brain vol. 8 BioMed Central 24 Feb. 2015 *
期刊 Holehonnur, Roopashri et al. The production of viral vectors designed to express large and difficult to express transgenes within neurons. Molecular brain vol. 8 BioMed Central 24 Feb. 2015

Also Published As

Publication number Publication date
CO2023000444A2 (es) 2023-01-26
EP4196171A1 (en) 2023-06-21
IL300294A (en) 2023-04-01
JP7860958B2 (ja) 2026-05-18
AU2021325717A1 (en) 2023-03-02
CL2023000419A1 (es) 2023-07-21
CA3188748A1 (en) 2022-02-17
PE20230914A1 (es) 2023-06-02
TW202221018A (zh) 2022-06-01
US20230295657A1 (en) 2023-09-21
WO2022034130A1 (en) 2022-02-17
CN116113441A (zh) 2023-05-12
PH12023550145A1 (en) 2024-03-18
KR20230044506A (ko) 2023-04-04
BR112023002374A2 (pt) 2023-03-21
CN116113441B (zh) 2026-06-09
AR123206A1 (es) 2022-11-09
JP2023537980A (ja) 2023-09-06
ZA202300378B (en) 2024-04-24
ECSP23016688A (es) 2023-04-28
MX2023001701A (es) 2023-03-09

Similar Documents

Publication Publication Date Title
CN116113441A (zh) 使用包含甲基cpg结合蛋白2(mecp2)启动子序列的核酸构建体的基因疗法
KR102946735B1 (ko) 오토페를린 유전자를 회복시키는 aav-매개된 유전자 치료요법
ES2819976T5 (es) Composiciones y usos médicos para la reprogramación de TCR con proteínas de fusión
KR102447083B1 (ko) 유도성 카스파제 및 사용 방법
CN100422320C (zh) 编码抗肌萎缩蛋白小基因的dna序列及其使用方法
CN101605899B (zh) 用于大量生产重组蛋白质的新载体和表达细胞系以及使用其生产重组蛋白质的方法
JP2022527917A (ja) 導入遺伝子発現のための操作されたアデノ随伴(aav)ベクター
KR20230167100A (ko) 안구 트랜스진 발현을 위한 조성물 및 방법
CN112512596A (zh) 治疗danon病的基因治疗载体
JPH10507928A (ja) ハイブリッドアデノウイルス−aavウイルスおよびその使用方法
JP7285022B2 (ja) 組換えヒトII型ミトコンドリアダイニン様GTPaseの遺伝子配列及びその使用
CN111235158B (zh) 用于表达重组人β-珠蛋白的病毒载体及其应用
CN110199028A (zh) 用于ii型黏多糖贮积症的基因治疗
KR101791296B1 (ko) 알츠하이머병 관련 돌연변이 유전자를 포함하는 발현 카세트, 벡터, 및 이를 이용하여 형질전환된 세포주
AU2018228881B2 (en) Gene therapy for ocular disorders
JP7540727B2 (ja) 網膜疾患の遺伝子治療
WO2016037931A1 (en) Nucleic acid constructs and expression vectors for gene therapy of acute porphyrias and other diseases
KR20250068800A (ko) 원추형 광수용체에서 유전자의 특이적 발현을 위한 프로모터
EP3870241A1 (en) Gene therapy
JP7805306B2 (ja) 遺伝子療法による治療
JP2026509301A (ja) 遺伝子治療
CN111850018B (zh) 多MHC基因型和抗原MiniGene组合文库及其构建方法和应用
JP2024525742A (ja) Kcnv2遺伝子治療
AU2019418750A1 (en) Modified adeno-associated viral vectors for use in genetic engineering
RU2808459C2 (ru) Геннотерапевтические векторы для лечения болезни данона